Table 2 Association between antibodies and risk of clinical malaria.

From: The association between naturally acquired IgG subclass specific antibodies to the PfRH5 invasion complex and protection from Plasmodium falciparum malaria

Antigen

Antibody

Comparison

HR (95% CI)

p Value

aHR(95% CI)

p Value

PfRh5

IgG (Total)

MvL

0.46 (0.2–1.06)

0.07

0.53 (0.23–1.25)

0.15

 

IgG (Total)

HvL

0.27 (0.1–0.72)

0.01

0.35 (0.12–0.96)

0.04

 

IgG1

MvL

0.81 (0.37–1.79)

0.61

0.98 (0.44–2.183)

0.97

 

IgG1

HvL

0.36 (0.13–.99)

0.05

0.46 (0.16–1.29)

0.14

 

IgG3

MvL

0.49 (0.28–0.84)

0.01

0.54 (0.31–0.95)

0.03

 

IgG3

HvL

0.26 (0.14–0.50)

0.01

0.35 (0.17–0.71)

0.03

PfRipr

IgG (Total)

MvL

0.41 (0.18–0.94)

0.04

0.51 (0.22–1.21)

0.13

 

IgG (Total)

HvL

0.2 (0.07–0.6)

0.004

0.24 (0.08–0.73)

0.01

 

IgG1

MvL

0.53 (0.23–1.22)

0.14

0.6 (0.26–1.38)

0.23

 

IgG1

HvL

0.38 (0.15–0.99)

0.05

0.48 (0.19–1.26)

0.14

 

IgG3

MvL

0.66 (0.38–1.13)

0.13

0.79 (0.45–1.38)

0.41

 

IgG3

HvL

0.29 (0.15–0.55)

<0.001

0.36 (0.18–0.72)

0.004

  1. Study participants were stratified into 3 equal groups according to low, medium or high levels of PfRH5-specific or PfRipr-specific antibodies antibodies. Hazard ratios were calculated comparing high versus low levels of antibodies (HvL) and medium versus low levels (MvL) of antibodies for the risk of symptomatic malaria over 6 months of follow-up; analysis was based on first episode only. Unadjusted hazard ratios (HR) and adjusted hazard ratios hazard ratios (aHR; adjusted for age and location of residence) with 95% confidence intervals [95% CI] were calculated. During the follow-up period, 80 children experienced at least one episode of clinical malaria.
Back to article page